JPH0579649B2 - - Google Patents
Info
- Publication number
- JPH0579649B2 JPH0579649B2 JP57186885A JP18688582A JPH0579649B2 JP H0579649 B2 JPH0579649 B2 JP H0579649B2 JP 57186885 A JP57186885 A JP 57186885A JP 18688582 A JP18688582 A JP 18688582A JP H0579649 B2 JPH0579649 B2 JP H0579649B2
- Authority
- JP
- Japan
- Prior art keywords
- plasma protein
- protein fraction
- aqueous solution
- fraction
- human plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 30
- 108010058237 plasma protein fraction Proteins 0.000 claims description 23
- 229940081857 plasma protein fraction Drugs 0.000 claims description 22
- 230000000304 vasodilatating effect Effects 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 10
- 108010017384 Blood Proteins Proteins 0.000 claims description 7
- 102000004506 Blood Proteins Human genes 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- 238000011026 diafiltration Methods 0.000 claims description 5
- 229910001415 sodium ion Inorganic materials 0.000 claims description 5
- 108010068307 Alpha-Globulins Proteins 0.000 claims description 4
- 102000002572 Alpha-Globulins Human genes 0.000 claims description 4
- 108010087504 Beta-Globulins Proteins 0.000 claims description 4
- 102000006734 Beta-Globulins Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 claims description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 3
- -1 caprylate ion Chemical class 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 229960005480 sodium caprylate Drugs 0.000 claims description 3
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 208000037319 Hepatitis infectious Diseases 0.000 claims description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 229910001414 potassium ion Inorganic materials 0.000 claims description 2
- VZZUJVDCIBINIT-YDALLXLXSA-N (2s)-2-acetamido-3-(1h-indol-3-yl)propanoic acid;sodium Chemical group [Na].C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 VZZUJVDCIBINIT-YDALLXLXSA-N 0.000 claims 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940116191 n-acetyltryptophan Drugs 0.000 claims 1
- 239000000243 solution Substances 0.000 description 28
- 239000000523 sample Substances 0.000 description 14
- 238000000502 dialysis Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 101800004538 Bradykinin Proteins 0.000 description 6
- 102400000967 Bradykinin Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 6
- 238000000108 ultra-filtration Methods 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010077861 Kininogens Proteins 0.000 description 2
- 102000010631 Kininogens Human genes 0.000 description 2
- 108090000113 Plasma Kallikrein Proteins 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
æ¬çºæã¯æ°èŠã®å®å®ãªè¡æŒ¿èçœè³ªïŒplasma
proteinïŒç»ååã³ãã®è£œé æ¹æ³ã®æäŸã«é¢ãã
ãã®ã§ããäžã€ãããç®çãšããŠãããç¹ã«æ¬çº
æã®ç®çã¯ãå®è³ªçã«é ¢é žã€ãªã³ãå«æããŠããª
ãïŒäººã®ïŒè¡æŒ¿èçœè³ªç»ååã³å®è³ªçã«è¡å§éäž
æåãå«æããŠããªãããããç»åãååŸããã
ãšã«ãããæ¬çºæã®ãã®ä»ã®ç®çã¯ã以äžã®èª¬æ
ã«ãã€ãŠæçœãšãªãã§ããããããã®èª¬æäžã§éš
åã³çŸåçã¯ãç¹ã«ä»ã®ããšããããªãéãã¯é
éã«ããã ç±åŠçãã人ã®è¡æŒ¿èçœè³ªç»åïŒPPFïŒãããš
ãã°ç±³åœç¹èš±ç¬¬2958628å·ã«èšèŒã®ãã®ãããšã
ã°ã·ãšãã¯ãäœèçœè¡çïŒhypoproteâinemiaïŒ
ãªã©ã®ãããªãè¡æŒ¿å¢éå€ã®äœ¿çšãå¿ èŠãšããç¶
æ ã®æ²»ççšãšããŠåºãçšããããŠãããéåžžã®äºº
ã®ä¿åè¡æŒ¿ã¯ãã©ã¡ãããšãããšé«ãå²åã§çžå
è¡æž é»çžïŒhomologous serum jaundiceïŒã®ã
ãŒã«ã¹ã«ããææããããããšããããšãèŠåºã
ããŠä»¥æ¥ãå®å®ãªäººã®PPFã®å¿ èŠãèªèãããŠ
ããã 倧éšåã®å Žåã«ãPPFã¯ãå¯äœçšãæäœéãš
ããããã«ãäœé床ã§æ£è ã«æäžãããããããª
ãããæè¿ãæ¯èŒçé«ãé床ã§PPF溶液ãæ³šå ¥
ããæ£è ã«ãèãããè¡å§ã®éäžãšå ç¶åèæµã®
å€åïŒä»¥äžè¡ç®¡æ¡åŒµæŽ»æ§ïŒvasodepressor
activityïŒãšèšãïŒãèªããããããã®è¡ç®¡æ¡åŒµ
掻æ§ã¯å€ãã®æ£è ã«å¯ŸããŠããããŠå±éºã§ããã 人ã®PPFäžã®âè¡ç®¡æ¡åŒµç©è³ªâïŒdepressor
substanceïŒã®ååšã¯ãç±³åœç¹èš±2958628å·ïŒä»¥
äžâ²628ãšèšãïŒäžã«èªããããŠãããè¡ç®¡æ¡åŒµæŽ»
æ§ã¯ç»åâïŒã«ãããã®ãšããããã³ã¯ã
ãHink et alïŒVox Song.ïŒïŒïŒ174ã186
ïŒ1957ïŒãã¯PPFã®æº¶æ¶²ããã®ç»åâïŒã®é€å»
ã¯è¡ç®¡æ¡åŒµæŽ»æ§ã®äœäžããææãäžããããšãèš
ããŠããã è¡ç®¡æ¡åŒµæŽ»æ§ã®äœäžã¯ç±³åœç¹èš±ç¬¬3876775å·
ïŒä»¥äžâ²775ãšèšãïŒã«ãã€ãŠããŸãéæãããã
ãã®ç¹èš±ã®çºæè ã¯ãè¡å§æ¡åŒµç©è³ªã¯1000ã
10000ã®ååéãæããããªããããã§ãã€ãŠã
äž»ãšããŠæ®ºèã®ããã«PPF溶液ãå ç±ããéã«
çãããã®ãšèšããŠãããâ²775ã®æ¹æ³ã«ãããŠ
ã¯ãç±åŠçããPPFã®æº¶æ¶²ããè¡šé¢æŽ»æ§åžçå€ã
éœã€ãªã³äº€ææš¹èãéå€éèãŸãã¯ã²ã«éç²
åãšæ¥è§ŠãããŠããã ç±³åœç¹èš±ç¬¬4251510å·ã«ãããŠã¯ãèçœè³ªç»å
ã«è¡ç®¡æ¡åŒµæŽ»æ§ãä»äžããããšãèªããããŠãã
ãã©ãžããã³ããããã²ã³åã³ãã¬ã«ãªã¯ã¬ã€ã³
掻æ§åç©è³ªãå®è³ªçã«å«æããŠããªãè¡æŒ¿èçœè³ª
ç»åãèšããŠããããã®ç¹èš±ã®æ¹æ³ã«ãããŠã¯ã
ãã³ã¯ã®äžæŸæ¶²ãã©ã¹ããäžæ§ã§ãçªé žè³ªç©
質ã«ãã€ãŠãåºæã®ãããã²ã³ã®ãã©ãžããã³ãž
ã®å®å šãªè»¢åãçããããããã«å åãªæéã«ã
ãã€ãŠåŠçããã次ãã§ããã³ã¯ã®ç»åâïŒã
ãåé¢ããã®ã¡ãè¡æŒ¿èçœè³ªç»åãåæ§æããã«
ã«ããã·ãããããŒãŒã«ãããã©ãžããã³ã®å®è³ª
çã«å®å šãªå解ãçããããããã«å åãªæéä¿
ã¡ã次ãã§éå€éåã³ïŒãŸãã¯éæéã«ãã€
ãŠããšã¿ããŒã«åã³æ®åãã©ãžããã³ãé€å»ã
ãã次ãã§ãæ®ç液ãã«ããªã«é žãããªãŠã ã
âã¢ã»ãã«âdlâããªãããã¢ã³ãçé žãããªãŠ
ã ãå¡©åãããªãŠã ãåã³é ¢é žãããªãŠã ã§æ§æ
ããããã æè¿ããžã€ãŒãã« ãªã ãã€ã¢ãªã·ã¹ã第ïŒ
å·»ã第ïŒå·ã235ã242é ïŒ1978ïŒåã³ãã©ã³ã¹ã¢
ã¯ã·ãšã³ ãªã 㶠ã¢ã¡ãªã«ã³ ãœãµãšãã€ãŒ
ãªã ã¢ãŒãã€ãã€ã·ã€ã« ã€ã³ã¿ãŒãã« ãª
ã«ã¬ã³ã¹ã第23å·»ã399ã405é ïŒ1977ïŒäžã§ãè
èçŸæ£ã®è¡æ¶²éææ²»çã«ãããåºå®ããŒã¹ãšããŠ
çšãããšãã«ãé ¢é žã€ãªã³ãè¡å§ã®äœäžãçãã
ããããšã瀺ãããã é ¢é žãããªãŠã ã¯ãçŸåšã®PPFïŒäººã®ïŒã®å·¥æ¥
çãªè£œé ã«ãããŠçšããããŠãããé ¢é žãããªãŠ
ã ã¯ãå®å®å€ãšå ±ã«ã溶åºæ¶²âïŒããæ²æŸ±ãã
ã湿ã€ãããŒã¹ãã®ä¹Ÿç¥ã«ãã€ãŠåŸã也ç¥ç²æ«ã®
溶液ã«å¯ŸããŠã人ã®PPFã®æº¶æ¶²ã®æ¿åºŠãå»ççš
éã«å¿ èŠãªç¯å²å ãããªãã¡ãïŒãªããã«åœã
130ã160ããªåœéã«å¢å€§ãããããã«å ããã ããããã¯ãPPFã®æº¶æ¶²äžã®é ¢é žã€ãªã³ã®å
åšã¯è¡ç®¡æ¡åŒµäœçšãããããããšãèŠåºãããã
ããããã°ã人ã®PPFäžã§ãå ¬ç¥ã®è¡ç®¡æ¡åŒµå€
ã®äžåšã«ãããŠãé ¢é žã€ãªã³ã¯è¡å§ã®äœäžãšå ç¶
åèæµã®å¢å€§ãäžããããã®åé¡ã«å¯Ÿããäžè§£æ±º
æ¹æ³ã¯ãPPFã®è£œé äžã®é ¢é žã€ãªã³ã®æ·»å ãé¿
ããŠãããšãã°å¡©åãããªãŠã ã®ãããªãå¥ã®ã
ããªãŠã ã€ãªã³æºãPPFã®æº¶æ¶²äžã«å ããããš
ã«ãã€ãŠããã®ãããªãŠã æ¿åºŠãäžèšã®ç¯å²å ã«
äžãããšããããšã§ãã€ããããããªããããã
ããã¯ããã®ããã«ããŠåŸãææã¯ãªãè¡ç®¡æ¡åŒµ
äœçšã瀺ãããšãèŠåºããã ããããã®ç 究ã¯ãäžæŸæ¶²âïŒããæ²æŸ±ãã
ã人ã®PPFã®æº¶æ¶²ãããã®ãããªãŠã ã€ãªã³æ¿
床ã®èª¿ç¯ã®ããã«é ¢é žãããªãŠã ãæ·»å ããªãã€
ãå Žåã«ãããã®æº¶æ¶²ã¯é©ãã¹ãããšã«çŽ2.5ã
ïŒããªåœéïŒã®é ¢é žã€ãªã³ïŒå å æ§é ¢é žã€ãª
ã³ïŒãå«æããŠããããšãæããã«ããããã®å
å æ§é ¢é žã€ãªã³ã¯ã人ã®PPF補é ã®ããã®ç¹èš±
ã®æ¹æ³ãããªãã¡ãâ²628ã®æ¹æ³ã«ãããŠçšããé ¢
é žå¡©ç·©è¡å€ç³»ããç±æ¥ãããã®ãšæãããã äžèšã®åé¡ã«å¯ŸåŠããŠãããããã¯è¡ç®¡æ¡åŒµæŽ»
æ§ãå®è³ªçã«æããŠãããäžã€é ¢é žã€ãªã³ãå®è³ª
çã«å«æããŠããªããããªãã¡ãPPF溶液ïŒãª
ããã«åœãçŽïŒããªåœéæªæºã®é ¢é žã€ãªã³ãå«æ
ããã«éããªããããªãã¡è¡ç®¡æ¡åŒµéã®é ¢é žã€ãª
ã³ãå«æããŠããªããå®å®ãªäººã®PPFã調補ã
ãã æ¬çºæã®æ¹æ³ã«ãããŠã¯ãé ¢é žã€ãªã³ãå«æã
ã人ã®PPFã®æº¶æ¶²ã«å¯ŸããŠéæéãé©çšãã
ããšã«ãã€ãŠãé ¢é žã€ãªã³ãé€å»ããã次ãã§ã
人ã®PPFãå®å®åããé ¢é žã€ãªã³ã®äžåšã§å¿ èŠ
ãªç¹å®ã®æ¿åºŠãšããã®ã¡æ®ºèããã æ¬çºæã®ç¬¬äžã®å©ç¹ã¯ããã®æ¹è¯ãã人ã®
PPFã¯ãæ害ãªè¡ç®¡æ¡åŒµäœçšã瀺ãããšãªãæ¯
èŒçé«ãæ³šå ¥é床ã§æ£è ã«æäžããããšãã§ãã
ãšããããšã§ããããã®çµæãšããŠãæ¬çºæã®æ¹
æ³ã«ãã€ãŠè£œé ããPPFã®æº¶æ¶²ã¯ãäžå±€åºãçš
éã«äœ¿çšããããšãã§ããäžã€äžå±€å€ãã®äººãã
ã®æçšãªè¡æŒ¿å¢éå€ã«ããå©çã享åããããšã
ã§ããã æ¬çºæã®æ¹æ³ã®ããã®åºçºææã¯ãè¡ç®¡æ¡åŒµé
ã®é ¢é žã€ãªã³ãå«æããè¡æŒ¿èçœè³ªç»åã§ããã
ããšãã°ã奜é©ãªåºçºææã¯â²628ã®æ¹æ³ïŒåèã®
ããã«ããã«æããïŒã«ãã€ãŠååŸããäžæŸæ¶²
âïŒããæ²æŸ±ãããïŒäººã®ïŒè¡æŒ¿èçœè³ªç»åã§ã
ããè¡æŒ¿èçœè³ªç»åïŒäººïŒãããªãã¡PPFïŒäººïŒ
ã¯ãç±³åœé£ååã³å»è¬åå±ïŒFDAïŒ21CFR64090
ã«ããâ²628ã®è£œåã«å¯ŸããŠé©çšãããå ¬åŒåã§ã
ããPPFïŒäººïŒã¯ãå°ãªããšã83ïŒ ã®ã¢ã«ããã³
ãš17ïŒ ä»¥äžã®ã¢ã«ãã¢åã³ããŒã¿ã°ãããªã³äžŠã³
ã«ïŒïŒ æªæºã®ã¬ã³ãã°ãããªã³ãå«æãããæ¬çº
æã®æ¹æ³ã¯ãããšãã°ãªãããŒã«ç¡«é žã¢ã³ã¢ããŠ
ã æ¹æ³ã®ãããªä»ã®æ¹æ³ã«ãã€ãŠãäžã€å ¬ç¥ã®ä»
ã®æºæ³ãããšãã°å šè¡åã³èç€è¡ããã補é ãã
è¡æŒ¿èçœè³ªç»åã«å¯ŸããŠããé©çšããããšãã§ã
ããéåžžã¯ã人ã®è¡æŒ¿èçœè³ªç»åã¯ãèçã®å±éº
ãé¿ããããã«ãããªãã¡ãéèçæææ§ãªãã
ããããã«ãäœããã®å®å®å€ã®ååšã§æ®ºèïŒç±åŠ
çïŒããã æ¬çºæã®æ¹æ³ã®é©çšã«éããŠã¯ãâ²628ã®äžæŸæ¶²
âïŒããå ããã®äžæŸæ¶²ã®ãšã¿ããŒã«å«éãçŽ
30ããŒã»ã³ããšãäžã€å ¬ç¥ã®ããã«ããŠPHãçŽ
4.6ã«äžããããšã«ãã€ãŠåŠçããŠãè¡æŒ¿èçœè³ª
ç»åã®æ²æŸ±ããããŒã¹ããååŸããããã®ããŒã¹
ããšè¬å€åŠçã«å容ãããæ°Žäžã«æžæ¿ããããšã
åŸã«ããã¯æº¶è§£ãããæ¬çºæã®æ¹æ³ã«åŸã€ãŠãã
ã®æº¶æ¶²ã«å ¬ç¥ã®æé ã«ããéæéãæœãããã®
ããã«ã¯ã溶液ãã10000ã®ååéã«ãããªãå€
ãæããèãããªãã¡ãçŽ10000ãããäœãåå
éãæããç©è³ªã¯ééãããçŽ10000ãããé«ã
ååéãæããç©è³ªã¯ééãããªãèãééãã
ããéå®ããç®çãªãã«äŸãšããŠæãããšãæ¬çº
æã®ãã®æ®µéã«ãããŠäœ¿çšããããšãã§ããé©åœ
ãªèã¯ãã¢ãã³ã³PM10åã³ã¢ãã³ã³UM10ïŒã¢ã
ã³ã³ã³ãŒãã¬ãŒã·ãšã³ãã¬ãã·ã³ãã³ãããµããŠ
ãŒã»ããïŒãããªãã¢PTGCïŒããªã㢠ã³ãŒãã¬
ãŒã·ãšã³ããããããªãŒããããµããŠãŒã»ããïŒã
ããã³ã³PM10ïŒããã³ã³ ã³ãŒãã¬ãŒã·ãšã³ã
ãŠã€ã³ããŒã³ãããµããŠãŒã»ããïŒãªã©ã§ããã
äžè¬ã«ã溶液ã¯ãæ··åç©ã®åçµæž©åºŠãããé«ãã
现èã®çé·ãä¿é²ããã»ã©é«ãã¯ãªã枩床ãããª
ãã¡ãçŽïŒã35âã奜ãŸããã¯ïŒã10âã®ç¯å²ã®
枩床ã§ãèãééããããé ¢é žã€ãªã³æ¿åºŠãçŽïŒ
ããªåœéïŒæªæºã奜ãŸããã¯ïŒããªåœéïŒæª
æºãæŽã«å¥œãŸããã¯äººã®è¡æ¶²è¡æŒ¿äžã«äžè¬ã«èªã
ãããæ¿åºŠãããªãã¡ã0.2ã0.65ããªåœéïŒã
ã«äœäžãããŸã§éæéãç¶ç¶ãããäžè¬ã«ãïŒ
ã24æéããã®çµæãéæããããã«å åã§ã
ãããã®æéã¯è©Šæã®éãšèã®è¡šé¢ç©ã«äŸåãã
詊飲éã倧ã§äžã€è¡šé¢ç©ãå°ããã»ã©ãéæé
æéãé·ããªãããã®éã«ãåœåã®æº¶æ¶²ãããªã
ã¡ãéæéã®é©çšåã®æº¶æ¶²ïŒéšåœãã«çŽïŒãïŒ
éšã®éæé液ãéãããããããã¯ãåœåã®æº¶
液ïŒéšåœãã«ïŒéšã®éæé液ãéããã®ã¡ã«ã
éæéã¯99ïŒ ãè¶ ããå¹çãšãªãããšãèªããŠ
ãããæ®ç液ã¯ãé ¢é žã€ãªã³ãå®è³ªçã«å«æããŠ
ããªã人ã®PPFãå«æããã æ®ç液ãã次ãã§âæçµå®¹åšâç¶æ ã確ç«ãã
ããã«ã次ã®ããã«åŠçããïŒPPFïŒäººïŒè£œåã
å®å®åããããã«ãã«ããªã«é žãããªãŠã ãšïŒ®â
ã¢ã»ãã«âdlâããªãããã¢ã³ããFDAã«ãã€
ãŠå¶å®ãããéçã«åŸã€ãŠãæ®ç液ã«å ãããæŽ
ã«ãçé žãããªãŠã ãå ããããšã«ãã€ãŠPHãå°
ãªããšãFDAã®å¶å®ããç¯å²å ãããªãã¡ãçŽ
6.4ã7.4ã奜ãŸããã¯çŽ6.7ã7.3ã«èª¿ç¯ãããæ
åŸã«ãFDAãèŠå®ããããã«ãçŽ130ã160ããª
åœéïŒã®ãããªãŠã ã€ãªã³æ¿åºŠãäžããããã«
ååãªå¡©åãããªãŠã ãæ®ç液ã«å ãããç¹ã«ã
å®å®ååã³PHãšã€ãªã³æ¿åºŠã®èª¿ç¯ã¯ãé ¢é žã€ãªã³
ã®äžåšã«ãããŠè¡ãªãããšã«æ³šæãã¹ãã§ããã ãã®ããã«ããŠåŸãæ®ç液åã³çæç©ã¯ããã
ããã®ç©è³ªã«ã€ããŠäžèšã®æ¿åºŠãæããŠããïŒã
ããªãŠã ã€ãªã³ã130ã160ããªåœéïŒïŒå¡©çŽ ã€
ãªã³100ã150ããªåœéïŒïŒã«ããªã«é žã€ãªã³ã
3.2ã4.8ããªåœéïŒïŒïŒ®âã¢ã»ãã«âdlâããª
ãããã¢ã³ã€ãªã³ã3.2ã4.8ããªåœéïŒïŒã«ãª
ãŠã ã€ãªã³ïŒããªåœéïŒæªæºïŒèçœè³ªã4.7ã
5.3ïŒ ïŒåã³é ¢é žã€ãªã³ãçŽïŒããªåœéïŒæªæºã
æ®ç液ã¯ãïŒåœãçŽ0.5g以äžã®çªè»åã®ååš
ã§ãéã¢ã¹ãã¹ããã€ã«ã¿ãŒãéããŠéããã
ãšã«ãã€ãŠãææŸåãããææŸåãã溶液ãå°ãª
ããšãçŽ48æéçŽïŒã10âã«ä¿ã¡äžã€55ã65âã«
çŽïŒãïŒæéå ç±ããã®ã¡ãåçµãããã«10â以
äžã«å·åŽãããç±åŠçãã溶液ããéåžžã¯çŽ0.20
ãã¯ãã³ã®å€§ããã®çµ¶å¯Ÿãã€ã«ã¿ãŒãéããé
ã«ãã€ãŠç¡èãšãããç¡èã®å šææãç¡èã®æçµ
容åšäžã«ç¡èçã«å ¥ãäžã€çŽ60âã«çŽ10æéå ç±
ããŠããã殺èããã â²628ã®æé ã«ãã€ãŠåŸã溶åºæ¶²âïŒããã®æ²
柱åŸã«ãPPFïŒäººïŒã®ããŒã¹ãã也ç¥ãã次ãã§
也ç¥ããç²æ«ã®ãéåžžã¯çŽïŒïŒ PPFïŒäººïŒã®ãæ°Ž
溶液ã調補ããããšããŸããæ¬çºæã®ç¯å²å ã§ã
ãããã®PPFïŒäººïŒã®æ°Žæº¶æ¶²ã«äžèšã®ãããªéæ
éãæœããŠãé ¢é žã€ãªã³æ¿åºŠãçŽïŒããªåœéïŒ
æªæºã奜ãŸããã¯ïŒããªåœéïŒæªæºã«äœäžã
ããã次ãã§ã溶液ãå®å®åããäžã€PPFïŒäººïŒ
ã®æžæ¿æ¶²ã«å¯ŸããŠå ã«èšããããã«ãé©åœãªPHãš
ã€ãªã³æ¿åºŠã«èª¿ç¯ãããç¶ãã®ã¡ã溶液ãåèšã®
ããã«å ç±ããŠãããã殺èããã æ¯èŒç奜é©æ§ã®å°ããæ¬çºæã®å®æœåœ¢æ ã«ãã
ãŠã¯ãåèšã®ããŒã¹ããŸãã¯ç²æ«ã氎溶液ãšããŠ
åŠæ¹ããŠããããé©åœãªè©Šè¬ã®æ·»å ã«ãã€ãŠæçµ
容åšæ¡ä»¶ãšããææŸåããã®ã¡ãæžèéããã
溶液ãçŽ60âã§çŽ10æéå ç±ããŠãããã殺èã
ãã殺èåŸã«æº¶æ¶²ãåèšã®æ¡ä»¶äžã«éæéã
ãŠãå®è³ªçã«é ¢é žã€ãªã³ãå«æããªãããã«ã
ããæçµå®¹åšæ¡ä»¶ãåã³ç¢ºä¿ããŠãææãç¡èã®
æçµå®¹åšäžã«å ¥ããã çæç©äžã®é ¢é žã€ãªã³ã®äžåšã確å®ãšãããã
ã®å¥ã®æ¹æ³ã¯ãâ²628ã®æ¹æ³ã®å šäœã«ããã€ãŠéé ¢
é žç·©è¡ç³»ãçšããããšã§ããããããããã°ãâ²
628ã®PH調ç¯æ®µéã«ãããŠãåç¹èš±ã®æ¹æ³ã®é ¢é ž
ãããªãŠã âé ¢é žç³»ã®ä»£ãã«ãè¬å€åŠçã«èš±å®¹ã
ããéé ¢é žç·©è¡ç³»ãçšããããã®ããã«ããŠãçŽ
ïŒããªåœéïŒæªæºã®é ¢é žã€ãªã³æ¿åºŠãæããå®
å®ãªäººã®PPFçæç©ãååŸããããšãã§ããã ãããŸã§ããªããããšãã°ãã©ãžããã³ããã¬
ã«ãªã¯ã¬ã€ã³æŽ»æ§åç©è³ªãªã©ã®ãããªå ¬ç¥ã®è¡ç®¡
æ¡åŒµå åããå¿ èŠã«å¿ããŠé€å»ããããšã«ãã€
ãŠãçæç©ãå®è³ªçã«è¡ç®¡æ¡åŒµæŽ»æ§ãæããŠããª
ãããšã確å®ã«ããããšã¯éèŠã§ãããããã¯ã
ããšãã°åŸæ¥ã®æç®ã®èšè¿°ã«éããŠå ã«åç §ãã
ãã®ã®ãããªå ¬ç¥ã®æé ã«ãã€ãŠéæããããšã
ã§ãããéæéæé ã¯ããã©ãžããã³ãå«æã
ãPPFãããããé€ããšããããšã«æ³šæããã
ãšã¯éèŠã§ããã å®æœäŸ æ¬çºæããå®èžã®äŸèšŒãšããŠå®æœäŸã«ãã€ãŠã
æŽã«å®èšŒããããããã®å®æœäŸã«ãããŠç 究ãã
è¡æŒ¿èçœè³ªç»åã¯ããã³ã¯ã®æ¹æ³ïŒâ²628ïŒã«ãã€
ãŠååŸããPPFïŒäººïŒã§ããããã®çæç©ã¯ãã
ãã«åèãšããŠæãããé£éŠèŠå®ã®æ³èŠã®é¡ç®21
ã®640.91åã³640.92é äžã«ç€ºããããããªçµæç©
ã«å¯ŸããèŠæ Œã«åèŽããã åç©ã¢ãã«ïŒ ççåŠçå®éšã«ãããŠã¯ãç¬ãã30mgïŒKgã®ã
ããªãŠã ãã³ããã«ãã¿ãŒã«ïŒãã ãã¿ãŒã«ãã¢
ããã ã©ãã©ããªãŒãºïŒã®éèå 泚å°ã«ãã€ãŠ
麻é ããæ¿ç®¡ããä»°è¥ãããäžã€å®€å 空æ°ãéã€
ããå³åŽå€§è ¿éšã®éèåéãè¡ãªããäžã€éèãš
åèã®äž¡æ¹ã«ã«ããŠãŒã¬ãæ¿å ¥ãããåè ã«ã¹ã
ããã³ãã¯ãåä»ããŠãè©Šéšæº¶æ¶²ããè¿œå ã®éº»é
å€ãšå ±ã«ããã®äžã«éããåŸè ã«å šèº«çãªè¡å§ã®
èšé²ã®ããã®ã°ã©ã¹ïŒåããªã°ã©ããšé©åœãªå¢å¹
åšã«æ¥ç¶ããã¹ã¿ãããã p23dbè¡å§å€æåšãå
ä»ããã å·ŠèžãéããŠãå·Šåã®éäžããå ç¶åèã«ãã¹
ã¿ãããã æµéèšã®ãããŒããåä»ããããã®ã
ããŒãããããªã°ã©ããã€ãŒãäžã«å³ãç»ãåºå
ãæããã¹ã¿ãããã PS2002åè¡æµèšã«æ¥ç¶ã
ããç³»ãå®å®ç¶æ ã«éãããšããå°ãªããšãïŒå
ã®ééã眮ããŠãéèäžã«60mlïŒåã®é床ã§æ³šå ¥
ãè¡ãªã€ããæ£ç¢ºãªè©äŸ¡ãåŸãããã«ããã¹ãŠã®
çµæããæ¯èŒå¯Ÿç §å€ã®çŸåçãšããŠè¡šãããã é ¢é žã€ãªã³ã®åæ é ¢é žã€ãªã³ã¯ãããŒã°ãã€ã€ãŒïŒâé µçŽ çåæ
æ¹æ³âã第ïŒå·»112é ã1974ïŒã«èšãããŠããé µçŽ
çãªåææ³ã«ãã€ãŠå®éãããããã¯é ¢é žå¡©ã®ã¢
ã»ãã«âè£é µçŽ ãžã®è»¢åã«åºã¥ããŠããã次ã
ã§ããããªããµãé ¢é žå¡©ãšåå¿ãããŠãã¯ãšã³é ž
ãšãããé µçŽ åå¿ã«ããããã³ãã³ã¢ããã¢ãã
ã³ãžãã¯ã¬ãªããã®éå ã«ãã340nmã«ãããåž
å 床ã®å¢å€§ã¯ãé ¢é žå¡©æ¿åºŠã«æ¯äŸããã å®æœäŸ ïŒ â²628ã®çæç©äžã®å å æ§é ¢é žå¡© â²628ã®çæåãå€ãã®å®éšïŒïŒ¡âïŒã§èª¿è£œ
ãããããããäžèšã®æ¹æ³ã«ãã€ãŠé ¢é žã€ãªã³æ¿
床ã«å¯ŸããŠåæããããã®çµæãäžè¡šã«èŠçŽã
ãã è©Šæ é ¢é žã€ãªã³ ïŒããªåœéïŒïŒ  3.56  3.22  3.61  2.44  2.51  4.75 å®æœäŸ ïŒ éæéãšéå€éã®æ¯èŒ ç¹èš±ã®æ¹æ³ã«åŸã€ãŠãâ²628ã®è£œåããã¢ã»ãã³
æŽæµãã颚也ããç²æ«ãšããŠã補é ããã泚å°çš
ã®æ°Žæ±ã®ãã®ç²æ«ã®ïŒïŒ 溶液ïŒïŒïŒãè©Šæã
ã調補ããã ãã®æº¶æ¶²ã®ïŒéšåïŒ500mlïŒïŒè©ŠæïŒããâ²775
ã®å®æœäŸïŒã«ç¥è¿°ããæé ã«åŸã€ãŠéå€éã«ã
ãããéå€éã®éã«æº¶æ¶²ã®éã¯100mlã«æžããã äžèšã®æº¶æ¶²ã®500mlãã€ã®ïŒéšåããã¢ãã³ã³
PM10èãçšããŠéæéãããéæéã¯ãå š
äœã§ããããïŒãè©Šæ(2)ãåã³ïŒãè©Šæ(1)ã容
éã®äº€æã®ããã«ã泚å°çšã®æ°Žã«å¯ŸããŠè¡ãªã€
ãã åè©Šæã«ã€ããŠã®é ¢é žã€ãªã³æ¿åºŠããåèšã®æ¹
æ³ã«ãã€ãŠå®éããããã®çµæãäžè¡šã«èŠçŽã
ãã è©Šæ é ¢é žã€ãªã³æ¿åºŠ ïŒããªåœéïŒïŒ  åºçºææ 2.95  éæé (1) ïŒå®¹éã®äº€æ 0.59 (2) ïŒå®¹éã®äº€æ 0.15  éå€é 1.97 å®æœäŸ ïŒ å®æœäŸïŒ§åã³ïŒš(2)ã®è¡ç®¡æ¡åŒµæŽ»æ§ããåèšã®å
ç©ã¢ãã«ãçšããŠæž¬å®ããã10ããªåœéïŒïŒè©Š
æïŒåã³20ããªåœéïŒïŒè©ŠæïŒã®é ¢é žãã
ãªãŠã ïŒNaAcïŒã®æ·»å ã䌎ãªãè©Šæããè©Šéš
ãããçµæãäžè¡šã«ç€ºããæ¯èŒãšããŠã¯ã¢ã«ãã
ã³ïŒäººïŒïŒïŒïŒ ïŒãçšããã
proteinïŒç»ååã³ãã®è£œé æ¹æ³ã®æäŸã«é¢ãã
ãã®ã§ããäžã€ãããç®çãšããŠãããç¹ã«æ¬çº
æã®ç®çã¯ãå®è³ªçã«é ¢é žã€ãªã³ãå«æããŠããª
ãïŒäººã®ïŒè¡æŒ¿èçœè³ªç»ååã³å®è³ªçã«è¡å§éäž
æåãå«æããŠããªãããããç»åãååŸããã
ãšã«ãããæ¬çºæã®ãã®ä»ã®ç®çã¯ã以äžã®èª¬æ
ã«ãã€ãŠæçœãšãªãã§ããããããã®èª¬æäžã§éš
åã³çŸåçã¯ãç¹ã«ä»ã®ããšããããªãéãã¯é
éã«ããã ç±åŠçãã人ã®è¡æŒ¿èçœè³ªç»åïŒPPFïŒãããš
ãã°ç±³åœç¹èš±ç¬¬2958628å·ã«èšèŒã®ãã®ãããšã
ã°ã·ãšãã¯ãäœèçœè¡çïŒhypoproteâinemiaïŒ
ãªã©ã®ãããªãè¡æŒ¿å¢éå€ã®äœ¿çšãå¿ èŠãšããç¶
æ ã®æ²»ççšãšããŠåºãçšããããŠãããéåžžã®äºº
ã®ä¿åè¡æŒ¿ã¯ãã©ã¡ãããšãããšé«ãå²åã§çžå
è¡æž é»çžïŒhomologous serum jaundiceïŒã®ã
ãŒã«ã¹ã«ããææããããããšããããšãèŠåºã
ããŠä»¥æ¥ãå®å®ãªäººã®PPFã®å¿ èŠãèªèãããŠ
ããã 倧éšåã®å Žåã«ãPPFã¯ãå¯äœçšãæäœéãš
ããããã«ãäœé床ã§æ£è ã«æäžãããããããª
ãããæè¿ãæ¯èŒçé«ãé床ã§PPF溶液ãæ³šå ¥
ããæ£è ã«ãèãããè¡å§ã®éäžãšå ç¶åèæµã®
å€åïŒä»¥äžè¡ç®¡æ¡åŒµæŽ»æ§ïŒvasodepressor
activityïŒãšèšãïŒãèªããããããã®è¡ç®¡æ¡åŒµ
掻æ§ã¯å€ãã®æ£è ã«å¯ŸããŠããããŠå±éºã§ããã 人ã®PPFäžã®âè¡ç®¡æ¡åŒµç©è³ªâïŒdepressor
substanceïŒã®ååšã¯ãç±³åœç¹èš±2958628å·ïŒä»¥
äžâ²628ãšèšãïŒäžã«èªããããŠãããè¡ç®¡æ¡åŒµæŽ»
æ§ã¯ç»åâïŒã«ãããã®ãšããããã³ã¯ã
ãHink et alïŒVox Song.ïŒïŒïŒ174ã186
ïŒ1957ïŒãã¯PPFã®æº¶æ¶²ããã®ç»åâïŒã®é€å»
ã¯è¡ç®¡æ¡åŒµæŽ»æ§ã®äœäžããææãäžããããšãèš
ããŠããã è¡ç®¡æ¡åŒµæŽ»æ§ã®äœäžã¯ç±³åœç¹èš±ç¬¬3876775å·
ïŒä»¥äžâ²775ãšèšãïŒã«ãã€ãŠããŸãéæãããã
ãã®ç¹èš±ã®çºæè ã¯ãè¡å§æ¡åŒµç©è³ªã¯1000ã
10000ã®ååéãæããããªããããã§ãã€ãŠã
äž»ãšããŠæ®ºèã®ããã«PPF溶液ãå ç±ããéã«
çãããã®ãšèšããŠãããâ²775ã®æ¹æ³ã«ãããŠ
ã¯ãç±åŠçããPPFã®æº¶æ¶²ããè¡šé¢æŽ»æ§åžçå€ã
éœã€ãªã³äº€ææš¹èãéå€éèãŸãã¯ã²ã«éç²
åãšæ¥è§ŠãããŠããã ç±³åœç¹èš±ç¬¬4251510å·ã«ãããŠã¯ãèçœè³ªç»å
ã«è¡ç®¡æ¡åŒµæŽ»æ§ãä»äžããããšãèªããããŠãã
ãã©ãžããã³ããããã²ã³åã³ãã¬ã«ãªã¯ã¬ã€ã³
掻æ§åç©è³ªãå®è³ªçã«å«æããŠããªãè¡æŒ¿èçœè³ª
ç»åãèšããŠããããã®ç¹èš±ã®æ¹æ³ã«ãããŠã¯ã
ãã³ã¯ã®äžæŸæ¶²ãã©ã¹ããäžæ§ã§ãçªé žè³ªç©
質ã«ãã€ãŠãåºæã®ãããã²ã³ã®ãã©ãžããã³ãž
ã®å®å šãªè»¢åãçããããããã«å åãªæéã«ã
ãã€ãŠåŠçããã次ãã§ããã³ã¯ã®ç»åâïŒã
ãåé¢ããã®ã¡ãè¡æŒ¿èçœè³ªç»åãåæ§æããã«
ã«ããã·ãããããŒãŒã«ãããã©ãžããã³ã®å®è³ª
çã«å®å šãªå解ãçããããããã«å åãªæéä¿
ã¡ã次ãã§éå€éåã³ïŒãŸãã¯éæéã«ãã€
ãŠããšã¿ããŒã«åã³æ®åãã©ãžããã³ãé€å»ã
ãã次ãã§ãæ®ç液ãã«ããªã«é žãããªãŠã ã
âã¢ã»ãã«âdlâããªãããã¢ã³ãçé žãããªãŠ
ã ãå¡©åãããªãŠã ãåã³é ¢é žãããªãŠã ã§æ§æ
ããããã æè¿ããžã€ãŒãã« ãªã ãã€ã¢ãªã·ã¹ã第ïŒ
å·»ã第ïŒå·ã235ã242é ïŒ1978ïŒåã³ãã©ã³ã¹ã¢
ã¯ã·ãšã³ ãªã 㶠ã¢ã¡ãªã«ã³ ãœãµãšãã€ãŒ
ãªã ã¢ãŒãã€ãã€ã·ã€ã« ã€ã³ã¿ãŒãã« ãª
ã«ã¬ã³ã¹ã第23å·»ã399ã405é ïŒ1977ïŒäžã§ãè
èçŸæ£ã®è¡æ¶²éææ²»çã«ãããåºå®ããŒã¹ãšããŠ
çšãããšãã«ãé ¢é žã€ãªã³ãè¡å§ã®äœäžãçãã
ããããšã瀺ãããã é ¢é žãããªãŠã ã¯ãçŸåšã®PPFïŒäººã®ïŒã®å·¥æ¥
çãªè£œé ã«ãããŠçšããããŠãããé ¢é žãããªãŠ
ã ã¯ãå®å®å€ãšå ±ã«ã溶åºæ¶²âïŒããæ²æŸ±ãã
ã湿ã€ãããŒã¹ãã®ä¹Ÿç¥ã«ãã€ãŠåŸã也ç¥ç²æ«ã®
溶液ã«å¯ŸããŠã人ã®PPFã®æº¶æ¶²ã®æ¿åºŠãå»ççš
éã«å¿ èŠãªç¯å²å ãããªãã¡ãïŒãªããã«åœã
130ã160ããªåœéã«å¢å€§ãããããã«å ããã ããããã¯ãPPFã®æº¶æ¶²äžã®é ¢é žã€ãªã³ã®å
åšã¯è¡ç®¡æ¡åŒµäœçšãããããããšãèŠåºãããã
ããããã°ã人ã®PPFäžã§ãå ¬ç¥ã®è¡ç®¡æ¡åŒµå€
ã®äžåšã«ãããŠãé ¢é žã€ãªã³ã¯è¡å§ã®äœäžãšå ç¶
åèæµã®å¢å€§ãäžããããã®åé¡ã«å¯Ÿããäžè§£æ±º
æ¹æ³ã¯ãPPFã®è£œé äžã®é ¢é žã€ãªã³ã®æ·»å ãé¿
ããŠãããšãã°å¡©åãããªãŠã ã®ãããªãå¥ã®ã
ããªãŠã ã€ãªã³æºãPPFã®æº¶æ¶²äžã«å ããããš
ã«ãã€ãŠããã®ãããªãŠã æ¿åºŠãäžèšã®ç¯å²å ã«
äžãããšããããšã§ãã€ããããããªããããã
ããã¯ããã®ããã«ããŠåŸãææã¯ãªãè¡ç®¡æ¡åŒµ
äœçšã瀺ãããšãèŠåºããã ããããã®ç 究ã¯ãäžæŸæ¶²âïŒããæ²æŸ±ãã
ã人ã®PPFã®æº¶æ¶²ãããã®ãããªãŠã ã€ãªã³æ¿
床ã®èª¿ç¯ã®ããã«é ¢é žãããªãŠã ãæ·»å ããªãã€
ãå Žåã«ãããã®æº¶æ¶²ã¯é©ãã¹ãããšã«çŽ2.5ã
ïŒããªåœéïŒã®é ¢é žã€ãªã³ïŒå å æ§é ¢é žã€ãª
ã³ïŒãå«æããŠããããšãæããã«ããããã®å
å æ§é ¢é žã€ãªã³ã¯ã人ã®PPF補é ã®ããã®ç¹èš±
ã®æ¹æ³ãããªãã¡ãâ²628ã®æ¹æ³ã«ãããŠçšããé ¢
é žå¡©ç·©è¡å€ç³»ããç±æ¥ãããã®ãšæãããã äžèšã®åé¡ã«å¯ŸåŠããŠãããããã¯è¡ç®¡æ¡åŒµæŽ»
æ§ãå®è³ªçã«æããŠãããäžã€é ¢é žã€ãªã³ãå®è³ª
çã«å«æããŠããªããããªãã¡ãPPF溶液ïŒãª
ããã«åœãçŽïŒããªåœéæªæºã®é ¢é žã€ãªã³ãå«æ
ããã«éããªããããªãã¡è¡ç®¡æ¡åŒµéã®é ¢é žã€ãª
ã³ãå«æããŠããªããå®å®ãªäººã®PPFã調補ã
ãã æ¬çºæã®æ¹æ³ã«ãããŠã¯ãé ¢é žã€ãªã³ãå«æã
ã人ã®PPFã®æº¶æ¶²ã«å¯ŸããŠéæéãé©çšãã
ããšã«ãã€ãŠãé ¢é žã€ãªã³ãé€å»ããã次ãã§ã
人ã®PPFãå®å®åããé ¢é žã€ãªã³ã®äžåšã§å¿ èŠ
ãªç¹å®ã®æ¿åºŠãšããã®ã¡æ®ºèããã æ¬çºæã®ç¬¬äžã®å©ç¹ã¯ããã®æ¹è¯ãã人ã®
PPFã¯ãæ害ãªè¡ç®¡æ¡åŒµäœçšã瀺ãããšãªãæ¯
èŒçé«ãæ³šå ¥é床ã§æ£è ã«æäžããããšãã§ãã
ãšããããšã§ããããã®çµæãšããŠãæ¬çºæã®æ¹
æ³ã«ãã€ãŠè£œé ããPPFã®æº¶æ¶²ã¯ãäžå±€åºãçš
éã«äœ¿çšããããšãã§ããäžã€äžå±€å€ãã®äººãã
ã®æçšãªè¡æŒ¿å¢éå€ã«ããå©çã享åããããšã
ã§ããã æ¬çºæã®æ¹æ³ã®ããã®åºçºææã¯ãè¡ç®¡æ¡åŒµé
ã®é ¢é žã€ãªã³ãå«æããè¡æŒ¿èçœè³ªç»åã§ããã
ããšãã°ã奜é©ãªåºçºææã¯â²628ã®æ¹æ³ïŒåèã®
ããã«ããã«æããïŒã«ãã€ãŠååŸããäžæŸæ¶²
âïŒããæ²æŸ±ãããïŒäººã®ïŒè¡æŒ¿èçœè³ªç»åã§ã
ããè¡æŒ¿èçœè³ªç»åïŒäººïŒãããªãã¡PPFïŒäººïŒ
ã¯ãç±³åœé£ååã³å»è¬åå±ïŒFDAïŒ21CFR64090
ã«ããâ²628ã®è£œåã«å¯ŸããŠé©çšãããå ¬åŒåã§ã
ããPPFïŒäººïŒã¯ãå°ãªããšã83ïŒ ã®ã¢ã«ããã³
ãš17ïŒ ä»¥äžã®ã¢ã«ãã¢åã³ããŒã¿ã°ãããªã³äžŠã³
ã«ïŒïŒ æªæºã®ã¬ã³ãã°ãããªã³ãå«æãããæ¬çº
æã®æ¹æ³ã¯ãããšãã°ãªãããŒã«ç¡«é žã¢ã³ã¢ããŠ
ã æ¹æ³ã®ãããªä»ã®æ¹æ³ã«ãã€ãŠãäžã€å ¬ç¥ã®ä»
ã®æºæ³ãããšãã°å šè¡åã³èç€è¡ããã補é ãã
è¡æŒ¿èçœè³ªç»åã«å¯ŸããŠããé©çšããããšãã§ã
ããéåžžã¯ã人ã®è¡æŒ¿èçœè³ªç»åã¯ãèçã®å±éº
ãé¿ããããã«ãããªãã¡ãéèçæææ§ãªãã
ããããã«ãäœããã®å®å®å€ã®ååšã§æ®ºèïŒç±åŠ
çïŒããã æ¬çºæã®æ¹æ³ã®é©çšã«éããŠã¯ãâ²628ã®äžæŸæ¶²
âïŒããå ããã®äžæŸæ¶²ã®ãšã¿ããŒã«å«éãçŽ
30ããŒã»ã³ããšãäžã€å ¬ç¥ã®ããã«ããŠPHãçŽ
4.6ã«äžããããšã«ãã€ãŠåŠçããŠãè¡æŒ¿èçœè³ª
ç»åã®æ²æŸ±ããããŒã¹ããååŸããããã®ããŒã¹
ããšè¬å€åŠçã«å容ãããæ°Žäžã«æžæ¿ããããšã
åŸã«ããã¯æº¶è§£ãããæ¬çºæã®æ¹æ³ã«åŸã€ãŠãã
ã®æº¶æ¶²ã«å ¬ç¥ã®æé ã«ããéæéãæœãããã®
ããã«ã¯ã溶液ãã10000ã®ååéã«ãããªãå€
ãæããèãããªãã¡ãçŽ10000ãããäœãåå
éãæããç©è³ªã¯ééãããçŽ10000ãããé«ã
ååéãæããç©è³ªã¯ééãããªãèãééãã
ããéå®ããç®çãªãã«äŸãšããŠæãããšãæ¬çº
æã®ãã®æ®µéã«ãããŠäœ¿çšããããšãã§ããé©åœ
ãªèã¯ãã¢ãã³ã³PM10åã³ã¢ãã³ã³UM10ïŒã¢ã
ã³ã³ã³ãŒãã¬ãŒã·ãšã³ãã¬ãã·ã³ãã³ãããµããŠ
ãŒã»ããïŒãããªãã¢PTGCïŒããªã㢠ã³ãŒãã¬
ãŒã·ãšã³ããããããªãŒããããµããŠãŒã»ããïŒã
ããã³ã³PM10ïŒããã³ã³ ã³ãŒãã¬ãŒã·ãšã³ã
ãŠã€ã³ããŒã³ãããµããŠãŒã»ããïŒãªã©ã§ããã
äžè¬ã«ã溶液ã¯ãæ··åç©ã®åçµæž©åºŠãããé«ãã
现èã®çé·ãä¿é²ããã»ã©é«ãã¯ãªã枩床ãããª
ãã¡ãçŽïŒã35âã奜ãŸããã¯ïŒã10âã®ç¯å²ã®
枩床ã§ãèãééããããé ¢é žã€ãªã³æ¿åºŠãçŽïŒ
ããªåœéïŒæªæºã奜ãŸããã¯ïŒããªåœéïŒæª
æºãæŽã«å¥œãŸããã¯äººã®è¡æ¶²è¡æŒ¿äžã«äžè¬ã«èªã
ãããæ¿åºŠãããªãã¡ã0.2ã0.65ããªåœéïŒã
ã«äœäžãããŸã§éæéãç¶ç¶ãããäžè¬ã«ãïŒ
ã24æéããã®çµæãéæããããã«å åã§ã
ãããã®æéã¯è©Šæã®éãšèã®è¡šé¢ç©ã«äŸåãã
詊飲éã倧ã§äžã€è¡šé¢ç©ãå°ããã»ã©ãéæé
æéãé·ããªãããã®éã«ãåœåã®æº¶æ¶²ãããªã
ã¡ãéæéã®é©çšåã®æº¶æ¶²ïŒéšåœãã«çŽïŒãïŒ
éšã®éæé液ãéãããããããã¯ãåœåã®æº¶
液ïŒéšåœãã«ïŒéšã®éæé液ãéããã®ã¡ã«ã
éæéã¯99ïŒ ãè¶ ããå¹çãšãªãããšãèªããŠ
ãããæ®ç液ã¯ãé ¢é žã€ãªã³ãå®è³ªçã«å«æããŠ
ããªã人ã®PPFãå«æããã æ®ç液ãã次ãã§âæçµå®¹åšâç¶æ ã確ç«ãã
ããã«ã次ã®ããã«åŠçããïŒPPFïŒäººïŒè£œåã
å®å®åããããã«ãã«ããªã«é žãããªãŠã ãšïŒ®â
ã¢ã»ãã«âdlâããªãããã¢ã³ããFDAã«ãã€
ãŠå¶å®ãããéçã«åŸã€ãŠãæ®ç液ã«å ãããæŽ
ã«ãçé žãããªãŠã ãå ããããšã«ãã€ãŠPHãå°
ãªããšãFDAã®å¶å®ããç¯å²å ãããªãã¡ãçŽ
6.4ã7.4ã奜ãŸããã¯çŽ6.7ã7.3ã«èª¿ç¯ãããæ
åŸã«ãFDAãèŠå®ããããã«ãçŽ130ã160ããª
åœéïŒã®ãããªãŠã ã€ãªã³æ¿åºŠãäžããããã«
ååãªå¡©åãããªãŠã ãæ®ç液ã«å ãããç¹ã«ã
å®å®ååã³PHãšã€ãªã³æ¿åºŠã®èª¿ç¯ã¯ãé ¢é žã€ãªã³
ã®äžåšã«ãããŠè¡ãªãããšã«æ³šæãã¹ãã§ããã ãã®ããã«ããŠåŸãæ®ç液åã³çæç©ã¯ããã
ããã®ç©è³ªã«ã€ããŠäžèšã®æ¿åºŠãæããŠããïŒã
ããªãŠã ã€ãªã³ã130ã160ããªåœéïŒïŒå¡©çŽ ã€
ãªã³100ã150ããªåœéïŒïŒã«ããªã«é žã€ãªã³ã
3.2ã4.8ããªåœéïŒïŒïŒ®âã¢ã»ãã«âdlâããª
ãããã¢ã³ã€ãªã³ã3.2ã4.8ããªåœéïŒïŒã«ãª
ãŠã ã€ãªã³ïŒããªåœéïŒæªæºïŒèçœè³ªã4.7ã
5.3ïŒ ïŒåã³é ¢é žã€ãªã³ãçŽïŒããªåœéïŒæªæºã
æ®ç液ã¯ãïŒåœãçŽ0.5g以äžã®çªè»åã®ååš
ã§ãéã¢ã¹ãã¹ããã€ã«ã¿ãŒãéããŠéããã
ãšã«ãã€ãŠãææŸåãããææŸåãã溶液ãå°ãª
ããšãçŽ48æéçŽïŒã10âã«ä¿ã¡äžã€55ã65âã«
çŽïŒãïŒæéå ç±ããã®ã¡ãåçµãããã«10â以
äžã«å·åŽãããç±åŠçãã溶液ããéåžžã¯çŽ0.20
ãã¯ãã³ã®å€§ããã®çµ¶å¯Ÿãã€ã«ã¿ãŒãéããé
ã«ãã€ãŠç¡èãšãããç¡èã®å šææãç¡èã®æçµ
容åšäžã«ç¡èçã«å ¥ãäžã€çŽ60âã«çŽ10æéå ç±
ããŠããã殺èããã â²628ã®æé ã«ãã€ãŠåŸã溶åºæ¶²âïŒããã®æ²
柱åŸã«ãPPFïŒäººïŒã®ããŒã¹ãã也ç¥ãã次ãã§
也ç¥ããç²æ«ã®ãéåžžã¯çŽïŒïŒ PPFïŒäººïŒã®ãæ°Ž
溶液ã調補ããããšããŸããæ¬çºæã®ç¯å²å ã§ã
ãããã®PPFïŒäººïŒã®æ°Žæº¶æ¶²ã«äžèšã®ãããªéæ
éãæœããŠãé ¢é žã€ãªã³æ¿åºŠãçŽïŒããªåœéïŒ
æªæºã奜ãŸããã¯ïŒããªåœéïŒæªæºã«äœäžã
ããã次ãã§ã溶液ãå®å®åããäžã€PPFïŒäººïŒ
ã®æžæ¿æ¶²ã«å¯ŸããŠå ã«èšããããã«ãé©åœãªPHãš
ã€ãªã³æ¿åºŠã«èª¿ç¯ãããç¶ãã®ã¡ã溶液ãåèšã®
ããã«å ç±ããŠãããã殺èããã æ¯èŒç奜é©æ§ã®å°ããæ¬çºæã®å®æœåœ¢æ ã«ãã
ãŠã¯ãåèšã®ããŒã¹ããŸãã¯ç²æ«ã氎溶液ãšããŠ
åŠæ¹ããŠããããé©åœãªè©Šè¬ã®æ·»å ã«ãã€ãŠæçµ
容åšæ¡ä»¶ãšããææŸåããã®ã¡ãæžèéããã
溶液ãçŽ60âã§çŽ10æéå ç±ããŠãããã殺èã
ãã殺èåŸã«æº¶æ¶²ãåèšã®æ¡ä»¶äžã«éæéã
ãŠãå®è³ªçã«é ¢é žã€ãªã³ãå«æããªãããã«ã
ããæçµå®¹åšæ¡ä»¶ãåã³ç¢ºä¿ããŠãææãç¡èã®
æçµå®¹åšäžã«å ¥ããã çæç©äžã®é ¢é žã€ãªã³ã®äžåšã確å®ãšãããã
ã®å¥ã®æ¹æ³ã¯ãâ²628ã®æ¹æ³ã®å šäœã«ããã€ãŠéé ¢
é žç·©è¡ç³»ãçšããããšã§ããããããããã°ãâ²
628ã®PH調ç¯æ®µéã«ãããŠãåç¹èš±ã®æ¹æ³ã®é ¢é ž
ãããªãŠã âé ¢é žç³»ã®ä»£ãã«ãè¬å€åŠçã«èš±å®¹ã
ããéé ¢é žç·©è¡ç³»ãçšããããã®ããã«ããŠãçŽ
ïŒããªåœéïŒæªæºã®é ¢é žã€ãªã³æ¿åºŠãæããå®
å®ãªäººã®PPFçæç©ãååŸããããšãã§ããã ãããŸã§ããªããããšãã°ãã©ãžããã³ããã¬
ã«ãªã¯ã¬ã€ã³æŽ»æ§åç©è³ªãªã©ã®ãããªå ¬ç¥ã®è¡ç®¡
æ¡åŒµå åããå¿ èŠã«å¿ããŠé€å»ããããšã«ãã€
ãŠãçæç©ãå®è³ªçã«è¡ç®¡æ¡åŒµæŽ»æ§ãæããŠããª
ãããšã確å®ã«ããããšã¯éèŠã§ãããããã¯ã
ããšãã°åŸæ¥ã®æç®ã®èšè¿°ã«éããŠå ã«åç §ãã
ãã®ã®ãããªå ¬ç¥ã®æé ã«ãã€ãŠéæããããšã
ã§ãããéæéæé ã¯ããã©ãžããã³ãå«æã
ãPPFãããããé€ããšããããšã«æ³šæããã
ãšã¯éèŠã§ããã å®æœäŸ æ¬çºæããå®èžã®äŸèšŒãšããŠå®æœäŸã«ãã€ãŠã
æŽã«å®èšŒããããããã®å®æœäŸã«ãããŠç 究ãã
è¡æŒ¿èçœè³ªç»åã¯ããã³ã¯ã®æ¹æ³ïŒâ²628ïŒã«ãã€
ãŠååŸããPPFïŒäººïŒã§ããããã®çæç©ã¯ãã
ãã«åèãšããŠæãããé£éŠèŠå®ã®æ³èŠã®é¡ç®21
ã®640.91åã³640.92é äžã«ç€ºããããããªçµæç©
ã«å¯ŸããèŠæ Œã«åèŽããã åç©ã¢ãã«ïŒ ççåŠçå®éšã«ãããŠã¯ãç¬ãã30mgïŒKgã®ã
ããªãŠã ãã³ããã«ãã¿ãŒã«ïŒãã ãã¿ãŒã«ãã¢
ããã ã©ãã©ããªãŒãºïŒã®éèå 泚å°ã«ãã€ãŠ
麻é ããæ¿ç®¡ããä»°è¥ãããäžã€å®€å 空æ°ãéã€
ããå³åŽå€§è ¿éšã®éèåéãè¡ãªããäžã€éèãš
åèã®äž¡æ¹ã«ã«ããŠãŒã¬ãæ¿å ¥ãããåè ã«ã¹ã
ããã³ãã¯ãåä»ããŠãè©Šéšæº¶æ¶²ããè¿œå ã®éº»é
å€ãšå ±ã«ããã®äžã«éããåŸè ã«å šèº«çãªè¡å§ã®
èšé²ã®ããã®ã°ã©ã¹ïŒåããªã°ã©ããšé©åœãªå¢å¹
åšã«æ¥ç¶ããã¹ã¿ãããã p23dbè¡å§å€æåšãå
ä»ããã å·ŠèžãéããŠãå·Šåã®éäžããå ç¶åèã«ãã¹
ã¿ãããã æµéèšã®ãããŒããåä»ããããã®ã
ããŒãããããªã°ã©ããã€ãŒãäžã«å³ãç»ãåºå
ãæããã¹ã¿ãããã PS2002åè¡æµèšã«æ¥ç¶ã
ããç³»ãå®å®ç¶æ ã«éãããšããå°ãªããšãïŒå
ã®ééã眮ããŠãéèäžã«60mlïŒåã®é床ã§æ³šå ¥
ãè¡ãªã€ããæ£ç¢ºãªè©äŸ¡ãåŸãããã«ããã¹ãŠã®
çµæããæ¯èŒå¯Ÿç §å€ã®çŸåçãšããŠè¡šãããã é ¢é žã€ãªã³ã®åæ é ¢é žã€ãªã³ã¯ãããŒã°ãã€ã€ãŒïŒâé µçŽ çåæ
æ¹æ³âã第ïŒå·»112é ã1974ïŒã«èšãããŠããé µçŽ
çãªåææ³ã«ãã€ãŠå®éãããããã¯é ¢é žå¡©ã®ã¢
ã»ãã«âè£é µçŽ ãžã®è»¢åã«åºã¥ããŠããã次ã
ã§ããããªããµãé ¢é žå¡©ãšåå¿ãããŠãã¯ãšã³é ž
ãšãããé µçŽ åå¿ã«ããããã³ãã³ã¢ããã¢ãã
ã³ãžãã¯ã¬ãªããã®éå ã«ãã340nmã«ãããåž
å 床ã®å¢å€§ã¯ãé ¢é žå¡©æ¿åºŠã«æ¯äŸããã å®æœäŸ ïŒ â²628ã®çæç©äžã®å å æ§é ¢é žå¡© â²628ã®çæåãå€ãã®å®éšïŒïŒ¡âïŒã§èª¿è£œ
ãããããããäžèšã®æ¹æ³ã«ãã€ãŠé ¢é žã€ãªã³æ¿
床ã«å¯ŸããŠåæããããã®çµæãäžè¡šã«èŠçŽã
ãã è©Šæ é ¢é žã€ãªã³ ïŒããªåœéïŒïŒ  3.56  3.22  3.61  2.44  2.51  4.75 å®æœäŸ ïŒ éæéãšéå€éã®æ¯èŒ ç¹èš±ã®æ¹æ³ã«åŸã€ãŠãâ²628ã®è£œåããã¢ã»ãã³
æŽæµãã颚也ããç²æ«ãšããŠã補é ããã泚å°çš
ã®æ°Žæ±ã®ãã®ç²æ«ã®ïŒïŒ 溶液ïŒïŒïŒãè©Šæã
ã調補ããã ãã®æº¶æ¶²ã®ïŒéšåïŒ500mlïŒïŒè©ŠæïŒããâ²775
ã®å®æœäŸïŒã«ç¥è¿°ããæé ã«åŸã€ãŠéå€éã«ã
ãããéå€éã®éã«æº¶æ¶²ã®éã¯100mlã«æžããã äžèšã®æº¶æ¶²ã®500mlãã€ã®ïŒéšåããã¢ãã³ã³
PM10èãçšããŠéæéãããéæéã¯ãå š
äœã§ããããïŒãè©Šæ(2)ãåã³ïŒãè©Šæ(1)ã容
éã®äº€æã®ããã«ã泚å°çšã®æ°Žã«å¯ŸããŠè¡ãªã€
ãã åè©Šæã«ã€ããŠã®é ¢é žã€ãªã³æ¿åºŠããåèšã®æ¹
æ³ã«ãã€ãŠå®éããããã®çµæãäžè¡šã«èŠçŽã
ãã è©Šæ é ¢é žã€ãªã³æ¿åºŠ ïŒããªåœéïŒïŒ  åºçºææ 2.95  éæé (1) ïŒå®¹éã®äº€æ 0.59 (2) ïŒå®¹éã®äº€æ 0.15  éå€é 1.97 å®æœäŸ ïŒ å®æœäŸïŒ§åã³ïŒš(2)ã®è¡ç®¡æ¡åŒµæŽ»æ§ããåèšã®å
ç©ã¢ãã«ãçšããŠæž¬å®ããã10ããªåœéïŒïŒè©Š
æïŒåã³20ããªåœéïŒïŒè©ŠæïŒã®é ¢é žãã
ãªãŠã ïŒNaAcïŒã®æ·»å ã䌎ãªãè©Šæããè©Šéš
ãããçµæãäžè¡šã«ç€ºããæ¯èŒãšããŠã¯ã¢ã«ãã
ã³ïŒäººïŒïŒïŒïŒ ïŒãçšããã
ãè¡šã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ 83ããŒã»ã³ã以äžã®ã¢ã«ããã³ãš17ããŒã»ã³
ã以äžã®ã¢ã«ãã¢åã³ããŒã¿ã°ãããªã³ããæ
ããé ¢é žã€ãªã³æ¿åºŠãè¡æŒ¿èçœè³ªç»åïŒãªããã«
åœããïŒããªåœéæªæºã§ããå®å®ãªäººã®è¡æŒ¿èçœ
質ç»åã ïŒ ããã«è¡ç®¡æ¡åŒµæŽ»æ§ãæããŠããªããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ç»åã ïŒ æŽã«ä»ã®è¡ç®¡æ¡åŒµæåãå«æããŠããªããç¹
èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ç»åã ïŒ æŽã«å®å®å€ãå«æãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒ
é èšèŒã®ç»åã ïŒ å®å®å€ãã¢ã»ãã«ããªãããã¢ã³ãããªãŠ
ã ãâã¢ã»ãã«ããªãããã¢ã³åã³ã«ããªã«é ž
ãããªãŠã ããæã矀ããéžã°ããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé èšèŒã®ç»åã ïŒ ããã«éâèçäŒææ§ã§ãããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé èšèŒã®ç»åã ïŒ 83ããŒã»ã³ã以äžã®ã¢ã«ããã³ãš17ããŒã»ã³
ã以äžã®ã¢ã«ãã¢åã³ããŒã¿ã°ãããªã³ããæ
ããé ¢é žã€ãªã³æ¿åºŠãè¡æŒ¿èçœè³ªç»åïŒãªããã«
åœããïŒããªåœéæªæºã§ããç¡è氎溶液ç¶ã®å®å®
ãªäººã®è¡æŒ¿èçœè³ªç»åã ïŒ è¡ç®¡æ¡åŒµæŽ»æ§ãæããŠããªããæ¥éãªéèå
æ³šå ¥ã«é©ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ç¡è
氎溶液ç¶ã®å®å®ãªäººã®è¡æŒ¿èçœè³ªç»åã ïŒ ïŒããŒã»ã³ãã®å®å®ãªè¡æŒ¿èçœè³ªãå«æã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ç¡è氎溶液ç¶ã®
å®å®ãªäººã®è¡æŒ¿èçœè³ªç»åã ïŒïŒ 6.4ã7.4ã®PHåã³130ã160ããªåœéïŒïŒã®
ãããªãŠã ã€ãªã³ã100ã150ããªåœéïŒïŒã®å¡©çŽ
ã€ãªã³ãè¡æŒ¿èçœè³ªç»åãå®å®åããéã®ã«ããª
ã«é žã€ãªã³åã³ïŒ®âã¢ã»ãã«âd1âããªããã
ã¢ã³ã€ãªã³ãïŒããªåœéïŒïŒæªæºã®ã«ãªãŠã ã€ãª
ã³ãå å«ãäžã€4.7ã5.3ããŒã»ã³ãã®èçœè³ªãå«
æããçµæãæãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒ
ã®ç¡è氎溶液ç¶ã®å®å®ãªäººã®è¡æŒ¿èçœè³ªç»åã ïŒïŒ é ¢é žã€ãªã³æ¿åºŠã0.2ã0.65ããªåœéïŒïŒ
ã§ãããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ç¡è氎溶液
ç¶ã®å®å®ãªäººã®è¡æŒ¿èçœè³ªç»åã ïŒïŒ è¡ç®¡æ¡åŒµæŽ»æ§ãæããŠããªããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®ç¡è氎溶液ç¶ã®å®å®ãªäººã®è¡æŒ¿
èçœè³ªç»åã ïŒïŒ ä»ã®è¡ç®¡æ¡åŒµæåãå«æããŠããªããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ç¡è氎溶液ç¶ã®å®å®ãªäºº
ã®è¡æŒ¿èçœè³ªç»åã ïŒïŒ 83ããŒã»ã³ã以äžã®ã¢ã«ããã³ãš17ããŒã»
ã³ã以äžã®ã¢ã«ãã¢åã³ããŒã¿ã°ãããªã³ããæ
ããé ¢é žã€ãªã³æ¿åºŠãè¡æŒ¿èçœè³ªç»åïŒãªããã«
åœããïŒããªåœéæªæºã§ããå®å®ãªäººã®è¡æŒ¿èçœ
質ç»åã®è£œé æ¹æ³ã«ãããŠãé ¢é žã€ãªã³ãå«æã
ãå®å®ãªäººã®è¡æŒ¿èçœè³ªç»åã®æ°Žæº¶æ¶²ããé ¢é žã€
ãªã³ã®ééã¯èš±ããã該è¡æŒ¿èçœè³ªã®ãã¹ãŠã®é
éãé»æ¢ããèœåãæããéææ¿Ÿéèãšã溶液äž
ã®é ¢é žã€ãªã³æ¿åºŠãè¡æŒ¿èçœè³ªç»åã®æ°Žæº¶æ¶²ïŒãª
ããã«åœããïŒããªåœéæªæºã«ãªããŸã§ïŒã24æ
éæ¥è§Šããã段éãå å«ããããšãç¹åŸŽãšããæ¹
æ³ã ïŒïŒ éææ¿Ÿéèã10000æªæºã®ååéãæãã
ç©è³ªã®ééã¯èš±ããã10000以äžã®ååéãæã
ãç©è³ªã®ééã¯é»æ¢ããèœåãæãããã®ã§ã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æ¹æ³ã ïŒïŒ æŽã«è©²æ°Žæº¶æ¶²ããèãšã®æ¥è§ŠåŸã«ã60âã®
枩床ã«ãããŠãå ç±ããŠæ®ºèãã段éãå å«ã
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æ¹æ³ã ïŒïŒ é ¢é žã€ãªã³ãå å«ããå®å®ãªäººã®è¡æŒ¿èçœ
質ç»åã®æ°Žæº¶æ¶²ããé ¢é žã€ãªã³ã®ééã¯èš±ããã
該è¡æŒ¿èçœè³ªã®ãã¹ãŠã®ééãé»æ¢ããèœåãæ
ããéææ¿Ÿéèãšã氎溶液äžã®é ¢é žã€ãªã³æ¿åºŠã
0.2ã0.65ããªåœéïŒïŒã«æžå°ãããŸã§ïŒã24æ
éæ¥è§Šããããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®æ¹
æ³ã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/316,201 US4391801A (en) | 1981-10-29 | 1981-10-29 | Plasma protein fraction substantially free of acetate ions |
US316201 | 1981-10-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5883630A JPS5883630A (ja) | 1983-05-19 |
JPH0579649B2 true JPH0579649B2 (ja) | 1993-11-04 |
Family
ID=23227983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57186885A Granted JPS5883630A (ja) | 1981-10-29 | 1982-10-26 | é ¢é žã€ãªã³ãå®è³ªçã«å«æããŠããªãè¡æŒ¿èçœè³ªç»å |
Country Status (4)
Country | Link |
---|---|
US (1) | US4391801A (ja) |
JP (1) | JPS5883630A (ja) |
AT (1) | AT385661B (ja) |
DE (1) | DE3238620A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521287A (en) * | 1992-05-20 | 1996-05-28 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
GB9902000D0 (en) * | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
EP1398038B2 (en) * | 2000-02-08 | 2011-01-26 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
US8632785B2 (en) | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
PL375539A1 (en) * | 2002-11-25 | 2005-11-28 | Octapharma Ag | Prekallikrein depleted plasma derived albumin fraction |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5396315A (en) * | 1977-01-26 | 1978-08-23 | Plasmesco Ag | Preparation of serum protein composition for vein administeration |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390074A (en) * | 1942-02-09 | 1945-12-04 | Research Corp | Protein product and process |
US2958628A (en) * | 1957-02-21 | 1960-11-01 | Cutter Lab | Heat treatable plasma protein product and method of preparation |
US3100737A (en) * | 1958-02-05 | 1963-08-13 | Auerswald Wilhelm | Method of preparing a plasma protein solution free of active hepatitis virus and product produced thereby |
JPS5620287B2 (ja) * | 1972-06-19 | 1981-05-13 | ||
JPS5417002B2 (ja) * | 1974-02-18 | 1979-06-27 | ||
US4136094A (en) * | 1977-08-31 | 1979-01-23 | The Regents Of The University Of Minnesota | Preparation of intravenous human and animal gamma globulins and isolation of albumin |
DE2902158A1 (de) * | 1979-01-20 | 1980-07-31 | Biotest Serum Institut Gmbh | Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen |
US4251510A (en) * | 1979-08-15 | 1981-02-17 | Cutter Laboratories, Inc. | Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production |
-
1981
- 1981-10-29 US US06/316,201 patent/US4391801A/en not_active Expired - Lifetime
-
1982
- 1982-10-19 DE DE19823238620 patent/DE3238620A1/de not_active Ceased
- 1982-10-26 JP JP57186885A patent/JPS5883630A/ja active Granted
- 1982-10-28 AT AT0394982A patent/AT385661B/de not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5396315A (en) * | 1977-01-26 | 1978-08-23 | Plasmesco Ag | Preparation of serum protein composition for vein administeration |
Also Published As
Publication number | Publication date |
---|---|
ATA394982A (de) | 1987-10-15 |
DE3238620A1 (de) | 1983-05-11 |
US4391801A (en) | 1983-07-05 |
JPS5883630A (ja) | 1983-05-19 |
AT385661B (de) | 1988-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1142431A (en) | Virus-inactivated hgi-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, for preparing same and leukopenia curative containing same | |
US5099003A (en) | Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii | |
DE3400413C2 (ja) | ||
US4318902A (en) | Concentrated immunoglobulin solution suited for intravenous administration | |
US5122373A (en) | Immunoglobulin-g-containing fraction | |
JPH03503287A (ja) | çäœã«é©åãªãŠã£ã«ã¹äžæŽ»æ§åã¢ã«ããã³ | |
JPS6030291B2 (ja) | 人é¡ç²çã®ååå¢æ®ãä¿é²ããïœïœïœç³èçœè³ªãïœïœïœç³èçœè³ªã®è£œé æ³åã³ïœïœïœç³èçœè³ªãå«æããçœè¡çæžå°çæ²»çå€ | |
JPH0253408B2 (ja) | ||
HU182554B (en) | Process for producing preparation of serum protein for intravenous application | |
Dogon et al. | Characterization of an antibacterial factor in human parotid secretions, active against Lactobacillus casei | |
US4137307A (en) | Process for preparing haptoglobin aqueous solution using strong anion exchanger | |
JPH0579649B2 (ja) | ||
JPS58225023A (ja) | αâïŒâãããã€ããŒãŒé»å®³å€ã®è£œæ³ | |
US4061735A (en) | Haptoglobin in aqueous solution and process for preparing the same | |
JP4010573B2 (ja) | äœæž©æ®ºèäžã®è¡æŒ¿ãå®å®åããããã®çµæç©ããã³æ²»çåŠççšéã®ããã®äœæž©æ®ºèè¡æŒ¿æº¶æ¶² | |
JPS63165328A (ja) | çµç¹ã¿ã³ãã¯ïœïœïŒå«æå»è¬ | |
EP0253313B1 (en) | Process for heat treating chemically unmodified gamma-globulin | |
EP0011739B1 (en) | Process for obtaining blood coagulation factor xiii derived from human placenta | |
JPS6236326A (ja) | é è¡åšçŸæ£æ²»çå€ | |
DK166713B1 (da) | Fremgangsmaade til inaktivering af stoffer, der foraarsager uforenelighedsreaktioner i immunglobulinholdige blodfraktioner til terapeutisk eller profylaktisk anvendelse samt fremstilling af en immunglobulinholdig blodfraktion | |
FI96918B (fi) | Koostumus veriplasman stabiloimiseksi pastöroinnin aikana | |
EP0449897B1 (en) | A pure factor i protein and a process for producing said protein | |
SE451844B (sv) | Glykoprotein, forfarande for framstellning derav samt terapeutiskt medel innehallande nemnda glykoprotein | |
JPS59501546A (ja) | ã¬ã³ãã°ãããªã³å«æçµæç©ã®è£œé æ³ | |
JPS6030292B2 (ja) | 人é¡ç²çã®ååå¢æ®ãä¿é²ããå ç±åŠçïœïœïœïœïœåã³ïœïœïœïœïœã®å ç±åŠçæ³ |